Download Entire File
Total Page:16
File Type:pdf, Size:1020Kb
Annual Report 2011 CSR Data Book Relationship with Our Stakeholders Based on Takeda-ism Takeda Pharmaceutical Company Limited CSR Data Book Annual Report 2011—Takeda Pharmaceutical Company Limited Contents 2 Our Stakeholders The Environment 3 Basic Policy on CSR 30 Environmental Management 4 United Nations Global Compact Takeda Group Environmental Action Plan ISO26000 33 Environmental Protection and Accident Prevention–Policies 6 Stakeholder-Centered Information Disclosure and Performance Linking the GC10 Principles with ISO 26000 34 Pharmaceutical Production Division Global EHS Policy and Guidelines ISO 26000 Core Subjects Reference Table 36 Reducing Environmental Risks 8 CSR Activities and Targets 40 Initiatives to Deal with Climate Change Water Resources Conservation Initiatives 42 Biodiversity Conservation Initiatives Culture Waste Reduction 10 44 Feature: Becoming a Sustainable Organization 46 Reduction in Releases of Chemical Substances [Interview] Toyoji Yoshida, Chief Administration Officer Air and Water Quality Protection 48 Environmental Communication/Environmental Monitors 14 Takeda’s 230-Year History Environmental Accounting 50 Environmental Impacts Associated with Takeda Group Business Activities Organizational Governance Message from the Site 16 Corporate Governance 52 Site Data/Views of an Independent Expert Crisis Management 18 CSR Management/Due Diligence Fair Operating Practices Stakeholder Engagement 54 Compliance Toward Fair Operating Practices/Initiatives in the Industry Human Rights 56 Fair Promotion Activities/Anti-Corruption 20 Human Rights Issues throughout the Value Chain Social Responsibility in the Value Chain 22 Initiatives throughout the Value Chain 58 Global Purchasing Policy/Employee Compliance Program Treatment of Employees Promoting Green Procurement 60 Intellectual Property Labor Practices 24 Global Human Resources Policy/Developing a Global Talent Base Consumer Issues 26 Global Employee Survey 62 Anti-Counterfeit Measures/Supplying Information Sharing Takeda-ism/Training System 64 Quality Assurance System 28 Work-Life Balance/Employment of People with Disabilities 68 Supplying High-Quality Pharmaceutical Products Health and Safety of Employees/Relations with Workers Unions Social Responsibility as a Global Pharmaceutical Company: Vaccine Business Community Involvement and Development 70 Policy for Corporate Citizenship Activities 72 Partnership with NGOs and NPOs/Corporate Foundations Support for Areas Affected by the Great East Japan Earthquake 74 Healthcare Support for Developing Countries Initiatives at Takeda Group Companies 100 Corporate Information Key Social Responsibility Indices 102 GRI Guidelines Reference Table 106 Reference Table for United Nations Global Compact Advanced Level COP 108 Third-Party Comment Editorial Policy Takeda issues an integrated Annual Report that incorporates non-financial information such as CSR activities. The CSR Data Book is issued as a separate volume containing detailed information about Takeda’s relationship with its stakeholders. At Takeda, we believe that the essence of CSR is To ensure our disclosure to stakeholders is as full corporate activities based on Takeda-ism that lead as possible, we have also compiled the CSR Data to successful development of superior pharma- Book. Available only in PDF format out of consider- ceutical products. In recognition of this, Takeda ation for the environment, the CSR Data Book has integrated non-financial information such as contains further details about the CSR information CSR information into its Annual Report since fiscal found in the Annual Report in a re-edited form. 2006 to actively disclose this information to The information is selected for its all-round impor- stakeholders. tance, to both Takeda and to society. Takeda’s Philosophy and Approach on Reference Guidelines Stakeholder Engagement Sustainability Reporting Guidelines: Guidelines issued by the Global Reporting Initiative that specify a For Takeda, stakeholder engagement means under- globally applicable framework for sustainability reports. standing the position and concerns of stakeholders and AA1000: then reflecting these in corporate activities and deci- Guidelines issued by British firm AccountAbility that specify a sion making. Takeda refers to the international AA1000 systematic process in which stakeholders are involved in the course of developing communication systems, etc. scheme for accountability to enhance its stakeholder ISO 26000: engagement efforts. Guidance standards for social responsibility published by the International Organization for Standardization. The standards Associated Information were designed to be used by all organizations in both advanced and developing countries. P.2 Our Stakeholders/Main Methods of Dialogue P.19 Stakeholder Engagement Key Association Memberships ・ Nippon Keidanren (Japan Business Federation) AA1000: Fundamental Principles ・ Keizai Doyukai (Japan Association of Corporate Executives) ・ Japan Pharmaceutical Manufacturers Association (JPMA) Inclusivity (Foundation Principle) ・ Osaka Pharmaceutical Manufacturers Association Fully involving stakeholders in developing and achieving an accountable and strategic response to sustainability Inquiries Takeda Pharmaceutical Company Limited Tokyo Head Office Materiality Corporate Communications Department Determining issues of relevance and significance to the 12-10, Nihonbashi 2-Chome Chuo-ku, Tokyo 103-8668, Japan organization and its stakeholders Tel: +81-3-3278-2111 Fax: +81-3-3278-2000 Website Responsiveness http://www.takeda.com/ Fully responding to the issues of stakeholders Scope of Reporting Consolidated subsidiaries of the Takeda Group *In some places the data covers only Takeda Pharmaceutical Company Limited but we intend to use consolidated data in future. Period of Reporting Fiscal 2010 (April 1, 2010 to March 31, 2011) *Some fiscal 2011 activities are included. Issue Date October 2011 (Previous issue: October 2010) Takeda CSR Data Book 2011 1 Takeda’s CSR Activities Our Stakeholders Stakeholders comprise all parties that are influenced by, and/or have an influence on, corporate activities. Main Method of Dialogue Through its pharmaceutical business, Takeda builds relationships of trust with medical ●Pharmaceutical information ac- professionals by providing high-quality pharmaceutical information services based on tivities scientific evidence. Takeda’s aim in this is to enable as many people as possible to be ●Provide information through cus- healthy. To allow us to develop a greater number of superior pharmaceutical products at tomer relations and through our website, etc. Relationship with a faster pace, and to better understand patients’ needs, we believe it is also vital to build good relationships with patients through organizations such as patient support groups. ●Hold seminars on healthcare, etc. Medical Professionals ●Provide information through ad- and Patients Associated Information P.62 Consumer Issues vertising In order to meet the expectations of shareholders and investors, Takeda will fulfill its ●Provide information through our economic responsibilities by pursuing sustainable growth. Takeda will also build Annual Report, website, and better relationships with shareholders and investors by continuing to disclose other media information in a timely and appropriate manner through its annual report and ●Shareholders meetings and inves- Relationship with tors’ briefings website. Shareholders ●IR activities and Investors ●Respond to CSR surveys by so- cially responsible investors Takeda fully recognizes that the development of society globally is closely linked to ●Implement programs in coopera- the Company’s own development. We will constantly consider how we as a tion with NGOs and NPOs corporate citizen should respond to the challenges facing global society and ●Activities through involvement in promote our initiatives accordingly. economic and industry groups ●Hold CSR lectures for professional ■Relationship with Public Organizations adults and students In the countries and regions where we conduct business, we will continue to contribute ●Exchange of views (dialogue) to those countries and associated regions, observing international rules and local laws, and cooperating with public organizations. ●Volunteer activities ■Relationship with Economic Organizations Takeda cooperates with the activities of economic organizations in regions where it Relationship with conducts business, recognizing that such activities contribute to the sustainable growth of Society global society. ■Relationship with Pharmaceutical Manufacturers’ Associations Takeda’s cooperation with pharmaceutical manufacturers’ associations goes beyond problems facing pharmaceutical industry at home in Japan. We also cooperate with pharma- ceutical manufacturers’ associations in the countries where we conduct business, to tackle global issues such as access to medicines and fighting disease in developing countries. Associated Information P.70 Community Involvement and Development Takeda is actively working in many ways to minimize the impact on the environ- ●Dialogue with local residents ment, including in relation to global warming, of the manufacturing process for living near plants and research pharmaceutical products. In addition, we are also taking steps to address biodiver- facilities Relationship with sity and water resource issues. ●Disclosure of information through Annual Report and website, etc. the Environment Associated Information P.30 The Environment Takeda considers